Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meriolin 3
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Meriolin 3 is a synthetic small molecule belonging to the class of pyrrolopyridines. It features a fused pyrrole and pyridine ring system substituted with a methoxy group and a pyrimidinyl amine moiety. Meriolin 3 has been studied primarily as an experimental pharmacological agent with notable inhibitory activity against fibroblast growth factor receptors (FGFRs), specifically FGFR1–FGFR4. These receptor tyrosine kinases are involved in cell growth and differentiation pathways; thus, inhibition by Meriolin 3 or its analogs has potential anticancer applications. The compound acts as an ATP-site competitive inhibitor of FGFRs and serves as a lead structure for further development of targeted cancer therapies[5].
- Other names
- 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine2-pyrimidinamine,4-(4-methoxy-1H-pyrrolo(2,3-b)pyridin-3-yl)-
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)GSK3 (Glycogen synthase kinase 3 beta)FGFR3 (Fibroblast growth factor receptor 3)CDK2 (Cyclin-dependent kinase 2)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)
Beyond the preview
Go deeper on meriolin 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meriolin 3.